When was Axsome Therapeutics founded?

Axsome Therapeutics was founded in 2012 and raised its 1st funding round 1 year after it was founded.

Where is Axsome Therapeutics located?

Axsome Therapeutics is headquartered in New York City, United States. It is registered at 22 Cortlandt Street 16 Floor New York, New York.

Who is the current CEO of Axsome Therapeutics?

Herriot Tabuteau of Axsome Therapeutics.

How many employees does Axsome Therapeutics have?

As of Aug 31, 2026, the latest employee count at Axsome Therapeutics is 1241.

Is Axsome Therapeutics a funded company?

Axsome Therapeutics is a funded company, having raised a total of $8.7M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 04, 2013.

When was the latest funding round of Axsome Therapeutics?

Axsome Therapeutics' latest funding was a $***** Post IPO round on Jan 07, 2019, with participation from 1 investor.

What is the annual revenue of Axsome Therapeutics?

Annual revenue of Axsome Therapeutics is between $500M and $1B as on Dec 31, 2025

Where does Axsome Therapeutics rank among its competitors?

Axsome Therapeutics ranks 58th amongst 2867 active competitors, of which 972 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Axsome Therapeutics?

Axsome Therapeutics' top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Axsome Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapeutics for the management of CNS disorders. The company's pipeline includes two late-stage product candidates, AXS-05 (bupropion and dextromethorphan) and AXS-02 (disodium zoledronate tetrahydrate) for multiple indications including treatment-resistant depression, agitation in Alzheimer's disease, complex regional pain syndrome (CRPS), Knee Osteo Arthritis related bone marrow lesions (BMLs) and chronic low back pain.

Website: www.axsome.com/
Email ID: *****@axsome.com
Registered Address: 22 Cortlandt Street 16 Floor New York, New York

Key Metrics

Founded Year

2012

Location

New York City, United States

Stage

Public

Total Funding

$8.7M in 6 rounds

Latest Funding Round

Post IPO, Jan 07, 2019, $*****

Investors

Venrock & 2 more

Ranked

58^th among 2867 active competitors

Annual Revenue

$500M - $1B as on Dec 31, 2025

Employee Count

1,241 as on Aug 31, 2026

Investment & Acquisitions

Baergic Bio & 2 more

Similar Companies

Jazz Pharmaceuticals & 581 more

Exit Details

Public

View Axsome Therapeutics' full profile

Axsome Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Axsome Therapeutics, Inc CIN: 45-4241907 , United States, Active	Dec 31, 2011	-	108 (As on Feb 28, 2022)	-
Axsome Therapeutics, Inc. CIN: 1579428 , United States, Active	Jan 11, 2012	$500M - $1B (As on Dec 31, 2025)	50 (As on Dec 31, 2022)	-

Axsome Therapeutics got listed on Nov 19, 2015.

Click here to take a look at Axsome Therapeutics's IPO in detail

Axsome Therapeutics has raised a total funding of $8.7M over 6 rounds. Its first funding round was on Mar 04, 2013. Its latest funding round was a Post IPO round on Jan 07, 2019 for $*****. 1 investor participated in its latest round. Axsome Therapeutics has 3 institutional investors.

Here is the list of recent funding rounds of Axsome Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 07, 2019	1296374	Post IPO	5315711	7512708	6775003	6311113
May 19, 2015	2164779	Series A	4531033	2436194	2817755	9957568
Jan 07, 2015	1266975	Conventional Debt	7567300	5568032	8868668	8736346

Access funding benchmarks and valuations. Sign up today!

View details of Axsome Therapeutics's funding rounds and investors

Axsome Therapeutics' employee count trend

Axsome Therapeutics has 1,241 employees as of Aug 26. Here is Axsome Therapeutics's employee count trend over the years:

Employee count trend for Axsome Therapeutics

Uncover Axsome Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Axsome Therapeutics include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Axsome Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, Khosla Ventures & 23 others	72/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
58th	Axsome Therapeutics 2012, New York City (United States), Public	Developer of therapeutic solutions for the management of CNS disorders	$8.7M	Venrock, Collage Venture Partners & 1 others	65/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Axsome Therapeutics's competitors? Click here to see the top ones

Axsome Therapeutics has acquired 3 companies including Baergic Bio, Baergic Bio and SUNOSI. Axsome Therapeutics has not made any investments as of now.

Here is the list of its acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Nov 06, 2025	Acquisition	Baergic Bio	2019	New York City (United States)
Nov 08, 2022	Acquisition	Baergic Bio	2019	New York City (United States)
Mar 29, 2022	Acquisition	SUNOSI	2014	Palo Alto (United States)